AAN 2016 Cerebrovascular Disease

Durlaza, an extended-release aspirin formulation, provides “sustained antiplatelet effects over 24 hours” in patients with type 2 diabetes mellitus (T2DM).

For both smokers and nonsmokers, adding clopidogrel to aspirin therapy is associated with a reduced risk of second stroke in the 90 days following a stroke or high-risk transient ischemic attack (TIA)—but that association is much stronger among smokers

Use of the norepinephrine oral prodrug, droxidopa, for the treatment of symptomatic neurogenic orthostatic hypotension is effective and “generally well tolerated across a range of ages,” including in those 75 years and older.

Unopposed estrogen hormone replacement therapy (HRT) significantly increases the risks for ischemic strokes when compared to combination estrogen and progesterone HRT, even after it is discontinued.

For patients with post-stroke lower limb spasticity, repeated injections of onabotulinumtoxinA over 1 year resulted in sustained benefit, final results from a phase 3 trial presented at the 68th Annual AAN Meeting have found.

Natalizumab, a treatment indicated for multiple sclerosis and Crohn’s disease, failed to meet its primary study endpoint of MRI-detected improvement in infarct volume from baseline to Day 5, according to a report at the 68th AAN Annual Meeting.

Patients 80 years of age or older who received intravenous tissue plasminogen activator (IV tPA) for acute ischemic stroke had double the mortality rate compared with those who were untreated, a study presented at the 68th AAN Annual Meeting concluded.

Neurologists, internists and cardiologists differ markedly in their prescribing beliefs when it comes to the prevention of ischemic stroke due to atrial fibrillation, according to survey results.

Individuals who used aspirin preceding a stroke display milder acute ischemic stroke severity, independent of acute infarct volume on diffusion-weighted MRI (DWI), analysis of a retrospective database presented at the 68th AAN Annual Meeting has found.

Early initiation of oral anticoagulation (OAC) after an acute ischemic stroke (AIS) is safe and can enhance recovery by lowering infarct volume and severity of stroke.